Insulin Effects in the Central Nervous System

Key points
- Insulin receptors are also expressed throughout the brain with particularly high concentrations in the hypothalamus, the hippocampus, and the cortex.
- Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, U.S.A.
- In humans, however, positron emission tomography (PET) studies repeatedly failed to reveal effects of hyperinsulinemia on brain glucose uptake.
- Nevertheless, an insulin effect on neuronal glucose oxidation or glial glycogen metabolism can not be excluded.
Insulin receptors are also expressed throughout the brain with particularly high concentrations in the hypothalamus, the hippocampus, and the cortex.
In humans, however, positron emission tomography (PET) studies repeatedly failed to reveal effects of hyperinsulinemia on brain glucose uptake. Since glucose transport is probably not an important downstream effector of insulin in neurons because this is largely facilitated by GLUT3 and, to a minor extent, GLUT1 (an insulin-independent glucose transporter) the human brain has been traditionally regarded as an insulin-insensitive organ.
Nevertheless, an insulin effect on neuronal glucose oxidation or glial glycogen metabolism can not be excluded. The most relevant neuronal insulin effect at the cellular level seems to be the inhibition of norepinephrine reuptake.
The resulting increase in synaptic cleft norepinephrine can have a variety of secondary effects, not only on the postsynaptic neuron but also on adjacent astrocytes (glial cells) via beta-adrenoceptor activation. Thus, insulin clearly has every potential to modulate central nervous system (CNS) activity.
Early work in animals suggested that insulin inhibits appetite at the CNS level.
When given directly into the brain, insulin-induced suppression of food intake and brain selective deletion of the insulin receptor resulted in hyperphagia, obesity, and metabolic insulin resistance in mice. Thus, the understanding of insulin regulation of appetite and its potential dysregulation in obesity should be of great relevance.
Given that insulin negatively regulates appetite in the CNS, the impact of CNS insulin on body weight regulation still remains widely unclear. In normal weight male subjects, insulin given intranasally over 8 weeks resulted in a weight loss of 1.3 kg and in a loss of 1.4 kg of body fat as determined by standard body impedance technique.
Waist circumference decreased by 1.6 cm and plasma leptin levels dropped by an average of 27%. However, in normal weight female subjects, the same intervention yielded an increase of body weight by 1 kg mainly due to increased extracellular water.
A recent magnetoencephalography study demonstrated differential insulin effects in lean and overweight subjects. In this study, the stimulatory insulin effect (expressed as difference to the placebo experiment) on theta activity was significantly smaller in obese than in lean subjects.
Moreover, the attenuation of insulin-induced changes in theta activity was inversely correlated with body mass index (BMI) in a multivariate analysis and positively with insulin-stimulated glucose disposal, i.e., metabolic insulin sensitivity in a univariate analysis.
These early findings suggest that obesity is associated with reduced cerebrocortical insulin sensitivity.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Diabetes & Hormones →
NewsInsulin differs between ethnicities, study finds
People have differing abilities to release and react to insulin depending on ethnicity, according to a new study from researchers at Lund University in Sweden, Stanford University and Kitasato University. The results…
28 June 2013
NewsType 1 diabetes : regenerate our own insulin cells ?
Patrick Collombat, Inserm Research Director and head of the Avenir team at the Institut de Biologie Valrose in Nice, has published new results concerning Type I diabetes. Researchers show that, in mice, the pancreas…
28 June 2013
NewsInsulin degludec lowers risk of recurrent low blood sugar or has similar risk to insulin glargine
Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia - low blood sugar - compared with the commercially available insulin glargine, a new meta-analysis…




